Long-term intermittent hypoxia in mice induces inflammatory pathways implicated in sleep apnea and steatohepatitis in humans.

Animal physiology Biological sciences Human Physiology Natural sciences Physiology

Journal

iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038

Informations de publication

Date de publication:
16 Feb 2024
Historique:
received: 02 08 2023
revised: 09 10 2023
accepted: 03 01 2024
medline: 2 2 2024
pubmed: 2 2 2024
entrez: 2 2 2024
Statut: epublish

Résumé

Obstructive sleep apnea (OSA) induces intermittent hypoxia (IH), an independent risk factor for non-alcoholic fatty liver disease (NAFLD). While the molecular links between IH and NAFLD progression are unclear, immune cell-driven inflammation plays a crucial role in NAFLD pathogenesis. Using lean mice exposed to long-term IH and a cohort of lean OSA patients (n = 71), we conducted comprehensive hepatic transcriptomics, lipidomics, and targeted serum proteomics. Significantly, we demonstrated that long-term IH alone can induce NASH molecular signatures found in human steatohepatitis transcriptomic data. Biomarkers (PPARs, NRFs, arachidonic acid, IL16, IL20, IFNB, TNF-α) associated with early hepatic and systemic inflammation were identified. This molecular link between IH, sleep apnea, and steatohepatitis merits further exploration in clinical trials, advocating for integrating sleep apnea diagnosis in liver disease phenotyping. Our unique signatures offer potential diagnostic and treatment response markers, highlighting therapeutic targets in the comorbidity of NAFLD and OSA.

Identifiants

pubmed: 38303705
doi: 10.1016/j.isci.2024.108837
pii: S2589-0042(24)00058-0
pmc: PMC10830848
doi:

Types de publication

Journal Article

Langues

eng

Pagination

108837

Informations de copyright

© 2024 The Author(s).

Déclaration de conflit d'intérêts

The authors declare no competing interests.

Auteurs

Jonathan Gaucher (J)

Hypoxia and Physio-Pathology Laboratory (HP2) INSERM U1300, University Grenoble Alpes, INSERM U1300, and Grenoble Alpes University Hospital, Grenoble, France.

Emilie Montellier (E)

Cancers and Biomarkers Team, Institute for Advanced Biosciences, University, INSERM U1209, CNRS UMR5309, University Grenoble Alpes, Grenoble, France.

Guillaume Vial (G)

Hypoxia and Physio-Pathology Laboratory (HP2) INSERM U1300, University Grenoble Alpes, INSERM U1300, and Grenoble Alpes University Hospital, Grenoble, France.

Florent Chuffart (F)

Epigenetics Regulation Team, Institute for Advanced Biosciences INSERM U1209, CNRS UMR5309, University Grenoble Alpes, Grenoble, France.

Maëlle Guellerin (M)

Hypoxia and Physio-Pathology Laboratory (HP2) INSERM U1300, University Grenoble Alpes, INSERM U1300, and Grenoble Alpes University Hospital, Grenoble, France.

Sophie Bouyon (S)

Hypoxia and Physio-Pathology Laboratory (HP2) INSERM U1300, University Grenoble Alpes, INSERM U1300, and Grenoble Alpes University Hospital, Grenoble, France.

Emeline Lemarie (E)

Hypoxia and Physio-Pathology Laboratory (HP2) INSERM U1300, University Grenoble Alpes, INSERM U1300, and Grenoble Alpes University Hospital, Grenoble, France.

Yoshiki Yamaryo Botté (YY)

Apicolipid Team, Institute for Advanced Biosciences INSERM U1209, CNRS UMR5309, University Grenoble Alpes, Grenoble, France.

Aya Dirani (A)

Hypoxia and Physio-Pathology Laboratory (HP2) INSERM U1300, University Grenoble Alpes, INSERM U1300, and Grenoble Alpes University Hospital, Grenoble, France.

Raoua Ben Messaoud (R)

Hypoxia and Physio-Pathology Laboratory (HP2) INSERM U1300, University Grenoble Alpes, INSERM U1300, and Grenoble Alpes University Hospital, Grenoble, France.

Marie Joyeux Faure (MJ)

Hypoxia and Physio-Pathology Laboratory (HP2) INSERM U1300, University Grenoble Alpes, INSERM U1300, and Grenoble Alpes University Hospital, Grenoble, France.

Diane Godin Ribuot (DG)

Hypoxia and Physio-Pathology Laboratory (HP2) INSERM U1300, University Grenoble Alpes, INSERM U1300, and Grenoble Alpes University Hospital, Grenoble, France.

Charlotte Costentin (C)

Hypoxia and Physio-Pathology Laboratory (HP2) INSERM U1300, University Grenoble Alpes, INSERM U1300, and Grenoble Alpes University Hospital, Grenoble, France.

Renaud Tamisier (R)

Hypoxia and Physio-Pathology Laboratory (HP2) INSERM U1300, University Grenoble Alpes, INSERM U1300, and Grenoble Alpes University Hospital, Grenoble, France.

Cyrille Y Botté (CY)

Apicolipid Team, Institute for Advanced Biosciences INSERM U1209, CNRS UMR5309, University Grenoble Alpes, Grenoble, France.

Saadi Khochbin (S)

Epigenetics Regulation Team, Institute for Advanced Biosciences INSERM U1209, CNRS UMR5309, University Grenoble Alpes, Grenoble, France.

Sophie Rousseaux (S)

Epigenetics Regulation Team, Institute for Advanced Biosciences INSERM U1209, CNRS UMR5309, University Grenoble Alpes, Grenoble, France.

Jean-Louis Pépin (JL)

Hypoxia and Physio-Pathology Laboratory (HP2) INSERM U1300, University Grenoble Alpes, INSERM U1300, and Grenoble Alpes University Hospital, Grenoble, France.

Classifications MeSH